REGISTRANT INFORMATION AND EMPLOYEE PLAN INFORMATION
The Company undertakes to provide without charge to each person to whom a Prospectus is delivered, upon written or oral request, a copy of any and all of the
information that has been incorporated by reference in the Post-Effective Amendment on Form S-3 to Form S-4 filed by the Company with the Securities and Exchange
Commission on May 21, 2021 (File No. 333-252232) (collectively, the Registration Statements) other than certain exhibits to such documents, relating to the shares covered hereby. These documents are incorporated
by reference in this Section 10(a) Prospectus. In addition, the Company undertakes to provide without charge to each Participant, upon written or oral request, a copy of the documents required to be delivered pursuant to Rule 428(b) under the
Securities Act of 1933, as amended (the Securities Act). Such requests, along with requests for information regarding the 2015 NantCell Plan and its administrators, should be directed to Jason Liljestrom, General Counsel,
ImmunityBio, Inc., 3530 John Hopkins Court, San Diego, California 92121, 858-633-0300.
The Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and subsequent Annual
Reports to Stockholders will be made available to all Participants on the Companys website at www.immunitybio.com. An additional copy of the prospectus or Annual Report, as applicable, will be furnished to a Participant upon request.
SUMMARY OF THE AMENDED AND RESTATED IMMUNITYBIO, INC.
2015 STOCK INCENTIVE PLAN
The statements contained herein concerning the terms and provisions of the 2015 NantCell Plan are summaries and do not purport to be complete. All such
statements are qualified in their entirety by reference to the full text of the 2015 NantCell Plan. In the event of any discrepancy, the terms of the 2015 NantCell Plan shall control. A copy of the 2015 NantCell Plan is included herein as Exhibit
A.
Purpose
The
NantCell, Inc. 2015 Stock Incentive Plan, which was amended and restated on March 4, 2021 to be renamed the Amended and Restated ImmunityBio, Inc. 2015 Stock Incentive Plan (the 2015 NantCell Plan) is intended to
encourage ownership of shares of Common Stock of the Company by certain employees, directors, and consultants of the Company and its affiliates (hereinafter referred to as Participants) in order to attract and retain such
people, to induce them to work for the benefit of the Company or of an affiliate and to provide additional incentive for them to promote the success of the Company or of an affiliate. The 2015 NantCell Plan provides for the granting of incentive
stock options (ISOs), non-qualified stock options (Non-Qualified Options, ISOs and
Non-Qualified Options are hereinafter referred to as Options), grants of shares of Common Stock, restricted stock and restricted stock units (together, Stock
Grants), and dividend equivalent rights and stock appreciation rights (together, Other Awards). Options, Other Awards and Stock Grants are collectively referred to herein as, Stock
Rights.
Offering
The Registration Statements cover the issuance of up to 1,094,377 shares of Common Stock, or the equivalent of such number of shares of Common Stock after the
Administrator (as defined below), in its sole discretion, has interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction in accordance with the 2015 NantCell Plan, which may be issued pursuant to
awards that were granted pursuant to the 2015 NantCell Plan, held by those who are not the Registrants employees as that term is defined in Form S-8 under the Securities Act, and outstanding
as of March 9, 2021, the effective date of the Merger (described below).
General Information about the 2015 NantCell
Plan
The address of the Company is 3530 John Hopkins Court, San Diego, California 92121.
The 2015 NantCell Plan was initially adopted by the Board of Directors of the Company and approved by its stockholders in 2015. The name of the Company was
subsequently changed to ImmunityBio, Inc., a Delaware corporation and a private company, before the Merger (as defined below). Pursuant to an Agreement and Plan of Merger, dated as of December 21, 2020 (the Merger
Agreement), by and among NantKwest, Inc. (NantKwest), the Company, and Nectarine Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the NantKwest (Merger Sub),
the Company merged with and into Merger Sub, with the Company surviving as a wholly-owned subsidiary of NantKwest (the Merger). In connection with the Merger, NantKwest was renamed ImmunityBio, Inc., and all awards granted
pursuant to the 2015 NantCell Plan were assumed by the Company. Following the Merger, all outstanding awards under the 2015 NantCell Plan were assumed by the Company and are now to be settled for shares of Common Stock of the Company. After the
Merger, no other awards shall be made under the 2015 NantCell Plan.
A-4